mRNA Cancer Vaccines And Therapeutics Market Report 2026

mRNA Cancer Vaccines And Therapeutics Market Overview

• mRNA Cancer Vaccines And Therapeutics market size has reached to $71.22 billion in 2025 • Expected to grow to $141.51 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: The Rise In Cancer Prevalence Fueling The Growth Of The Market Due To Increasing Lifestyle-Related And Environmental Risk Factors • Market Trend: Innovative Personalized Cancer Vaccines Aim To Boost Immune Response And Improve Survival In High-Risk Melanoma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under mRNA Cancer Vaccines And Therapeutics Market?

mRNA cancer vaccines and therapeutics refer to a type of medical treatment that utilizes messenger RNA (mRNA) to stimulate the immune system to recognize and fight cancer cells. It is used to deliver instructions to cells to produce therapeutic proteins or enzymes and help prime the immune system to identify and destroy cancer cells that express these antigens. The main mRNA cancer vaccines and therapeutics types are adeno carcinomas, mucinous carcinomas, and adenosquamous carcinomas. Adeno carcinomas refers to a type of cancer that forms in mucus-secreting glands throughout the body. It is applied for infectious disease, cancer, and others and it is used by several end users such as hospitals and clinics, ambulatory surgical centers, research institutes, and others.

What Is The mRNA Cancer Vaccines And Therapeutics Market Growth Forecast?

The mrna cancer vaccines and therapeutics market size is expected to see rapid growth in the next few years. It will grow to $141.51 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising global cancer burden, growing demand for personalized and targeted cancer treatments, expansion of mrna manufacturing capacity, increasing number of oncology clinical trials using mrna platforms, strategic collaborations between biotech and pharmaceutical companies. Major trends in the forecast period include rising adoption of personalized cancer vaccines, expansion of mrna-based therapeutics beyond oncology, growing focus on neoantigen-specific vaccine development, increased clinical pipeline for mrna cancer immunotherapies, higher investment in scalable mrna manufacturing platforms.

Global mRNA Cancer Vaccines And Therapeutics Market Segmentation

1) By Type: Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas 2) By Application: Cancer, Other Applications 3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End Users Subsegments: 1) By Adeno Carcinomas: Lung Adenocarcinomas, Colon Adenocarcinomas, Prostate Adenocarcinomas 2) By Mucinous Carcinomas: Mucinous Ovarian Cancer, Mucinous Breast Cancer, Mucinous Colorectal Cancer 3) By Adenosquamous Carcinomas: Pancreatic Adenosquamous Carcinoma, Cervical Adenosquamous Carcinoma, Esophageal Adenosquamous Carcinoma

What Is The Driver Of The mRNA Cancer Vaccines And Therapeutics Market?

The rising prevalence of cancer is expected to propel the growth of the mRNA cancer vaccine and therapeutic market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can invade and damage healthy tissues. The increasing incidence of cancer is largely attributed to factors such as sedentary lifestyles, poor dietary habits, and exposure to environmental toxins, all of which elevate the risk of developing various malignancies. mRNA cancer vaccines and therapeutics play a crucial role in advancing cancer treatment by enabling personalized, targeted immune responses that help the body identify and eliminate cancer cells more effectively, thereby improving treatment outcomes. For instance, in January 2024, according to the American Cancer Society, Inc., a US-based cancer advocacy organization in 2024, the United States is expected to witness over 611,000 cancer-related deaths, averaging more than 1,600 fatalities per day. Therefore, the rising prevalence of cancer is driving the growth of the mRNA cancer vaccine and therapeutic market.

Key Players In The Global mRNA Cancer Vaccines And Therapeutics Market

Major companies operating in the mrna cancer vaccines and therapeutics market are BioNTech SE, Moderna Therapeutics Inc., CureVac N.V., Arcturus Therapeutics Holdings Inc., Immatics Biotechnologies GmbH, Argos Therapeutics Inc., Anima Biotech, Translate Bio, eTheRNA Immunotherapies NV, Gritstone bio Inc., Neon Therapeutics, Codiak BioSciences, Cartesian Therapeutics, Replimune Group Inc., Precision BioSciences, Acuitas Therapeutics, Ethris GmbH, Strand Therapeutics, Crown Bioscience, Roche (Hoffmann-La Roche AG)

Global mRNA Cancer Vaccines And Therapeutics Market Trends and Insights

Major companies operating in the mRNA cancer vaccines and therapeutics market are focusing on developing innovative solutions, such as personalized neoantigen vaccines, to enhance immune response and improve survival outcomes in cancer patients. Personalized neoantigen vaccines are cancer therapies designed for each patient, using unique tumor-specific mutations to stimulate the immune system to target and destroy cancer cells. For instance, in July 2023, Merck & Co., Inc., a US-based research-intensive biopharmaceutical company, partnered with Moderna Therapeutics, Inc., a US-based biotechnology company, to initiate a Phase 3 randomized clinical trial (V940-001) to evaluate mRNA-4157 (V940) in combination with KEYTRUDA (pembrolizumab) as an adjuvant treatment for patients with resected high-risk (Stage IIB-IV) melanoma. This study follows positive results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, which showed a meaningful benefit of the combination over KEYTRUDA alone in reducing recurrence and distant metastasis risk. The Phase 3 trial aims to confirm these findings by assessing relapse-free survival and distant metastasis-free survival as primary and secondary endpoints, respectively.

What Are Latest Mergers And Acquisitions In The mRNA Cancer Vaccines And Therapeutics Market?

In June 2025 BioNTech SE, a Germany-based biotechnology company, acquired CureVac N.V. for an undisclosed amount. With the acquisition, BioNTech SE aims to strengthen the research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy candidates, marking a key milestone in its oncology strategy to advance innovative cancer treatments and establish new standards of care in the coming years. CureVac N.V. is a Germany-based company that develops mRNA-based cancer vaccines and therapies.

Regional Insights

North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the mRNA Cancer Vaccines And Therapeutics Market?

mRNA cancer vaccines and therapeutics market consists of sales of individualized cancer treatment mRNA vaccine, infectious disease treatment mRNA vaccine, and infection prevention mRNA vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the mRNA Cancer Vaccines And Therapeutics Market Report 2026?

The mrna cancer vaccines and therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mrna cancer vaccines and therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.